查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924723

催产素受体抑制剂市场依适应症、分子类型、给药途径、最终用户和通路划分－2026-2032年全球预测

Oxytocin Receptor Inhibitors Market by Indication, Molecule Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，催产素受体抑制剂市场价值将达到 13.2 亿美元，到 2026 年将成长至 14.5 亿美元，到 2032 年将达到 26.8 亿美元，复合年增长率为 10.58%。

关键市场统计数据
基准年 2025 13.2亿美元
预计年份：2026年 14.5亿美元
预测年份 2032 26.8亿美元
复合年增长率 (%) 10.58%

探讨影响催产素受体抑制剂在各个治疗领域发展的不断变化的科学、临床和运作现实的背景

催产素受体抑制剂领域处于神经药理学、母婴健康和精神疾病治疗的交叉学科领域，正吸引临床研究人员、生物技术公司和专科诊所日益增长的关注。受体生物学的进展以及对催产素在社会行为、子宫收缩和神经内分泌信号传导中作用的更深入理解，正在重新调整研发重点，并将潜在适应症范围扩展到传统应用之外。由此催生了一个涵盖胜肽类和小分子药物的多元化研发管线，研发人员正不断探索差异化的给药策略和以病人为中心的製剂。

精准生物学、製剂工程和数数位化临床试验的进步正在从根本上改变催产素受体抑制剂的研发路径。

过去几年，催产素受体抑制剂的发现、开发和给药方式发生了多项变革性变化。首先，精准生物学和生物标记驱动的临床试验的应用，使标靶检验从表观层面转向受体占有率和下游讯号传导的定量测量，从而使研发人员能够优先选择具有更强转化依据的候选药物。其次，药物化学和製剂科学的创新缩小了胜肽类药物和小分子药物之间的表现差距，扩大了口服和自我给药方案的可行性，从而提高了患者的依从性。

评估关税对药品原料和成品的累积影响，以及对药品研发者的供应链、筹资策略和临床供应连续性的影响。

对进口医药原料、胜肽合成耗材、生物製药及小分子药物征收或提高关税会产生累积效应，波及供应链、生产经济及临床开发物流。如果关税导致关键试剂和契约製造中间体的成本上升，申办方可能会重新评估其筹资策略，加快二级供应商的合格，并在某些情况下寻求将关键流程转移到近岸地区，以降低跨境贸易波动带来的风险。虽然这些调整可以降低风险，但通常需要前期投资对供应商审核、监管文件编制和规模化生产活动进行投资。

对多维细分框架的解读，该框架将适应症优先顺序、分子类别、给药途径、临床环境和分销管道与策略发展选择联繫起来。

严谨的细分框架为催产素受体抑制剂的临床优先事项、製剂选择和商业化路径提供了切实可行的见解。根据适应症，该领域涵盖泛自闭症障碍、产后出血、早产和思觉失调症，每种疾病都有其独特的未满足需求、临床终点和监管考量，这些都会影响研究设计和给药途径。泛自闭症障碍和思觉失调症的治疗重点在于药物能够穿透中枢神经系统并具有长期安全性，而产后出血和早产则优先考虑快速起效、可预测的子宫收缩调节以及与产科护理流程的整合。

比较美洲、欧洲、中东和非洲以及亚太地区在监管、临床研究、生产和准入方面的区域趋势。

区域趋势将对催产素受体抑制剂的研究基础设施、监管时间表、生产能力和商业性准入产生决定性影响。美洲拥有完善的研究生态系统，大规模的学术网络、在神经精神病学和产科研究方面经验丰富的成熟临床试验中心，以及优先考虑疗效比较和卫生经济价值证据的成熟支付方环境。这些优势使得高强度的临床计画得以开展，并为与医院系统早期合作创造了机会，检验治疗模式并产生真实世界的结果。

创新者、主要製药赞助商和生产合作伙伴之间的策略行动和合作模式将决定谁将推动催产素受体抑制剂计画。

活跃于催产素受体抑制剂领域的公司采取了不同的策略策略，这反映了它们各自的资源基础、技术能力和研发管线成熟度。生物技术创新者倾向于透过新型化学方法、递送平台和生物标记策略来实现早期差异化，旨在透过小规模、快速进行的概念验证研究来展示基于机制的讯号。这些赞助商通常倾向于与学术机构和受託研究机构(CRO) 建立灵活的合作模式，以加速转化研究并节省资金。

制定切实可行的策略重点，协调生物标记主导的研发、供应链韧性、支付方合作和商业化，以实现永续成功。

致力于将科学潜力转化为永续治疗方案的行业领导者应采取一系列综合行动，并兼顾科学严谨性和营运灵活性。首先，应优先发展转化生物标记项目，这些项目能够提供标靶结合和动态效应的早期、客观讯号，从而提高项目启动/终止决策的质量，并促进与监管机构的对话。同时，应投入资源研发化学和製剂策略，以最大限度地提高药物稳定性，并实现患者偏好的给药途径，从而将应用范围扩展到医院之外。

本分析的调查方法结合了面对面的专家访谈、系统的文献和註册资料审查、专利映射以及製造和分销评估，以确保证据的可靠性。

本分析的调查方法整合了多种互补途径，以确保研究结果的稳健性和可重复性。主要定性研究包括对直接参与神经精神病学和产科临床实验计画的临床医生、临床实验、法规事务专业人员和供应链管理人员进行深入访谈。这些访谈与对同侪审查文献、临床试验註册库和监管指导文件的系统性回顾相结合，检验机制假设、明确终点选择并识别主流试验设计创新。

整合科学潜力、营运限制和策略路径，将催产素受体抑制剂研究转化为临床应用治疗。

催产素受体抑制剂的研发环境具有坚实的科学基础、日益精细的转化研究以及复杂的操作权衡等特性。生物标记科学、製剂工程和分散式检测的进步为神经精神疾病和产科患者提供差异化治疗方法创造了机会。同时，计画发起人必须应对许多实际限制，例如胜肽类药物的生产能力、供应链风险、区域监管差异以及如何证明其具有符合支付方预期的显着临床获益。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 催产素受体抑制剂市场依适应症划分

  • 泛自闭症障碍
  • 产后出血
  • 早产
  • 思觉失调症

9. 依分子类型分類的催产素受体抑制剂市场

  • 胜肽
  • 低分子化合物

10. 催产素受体抑制剂市场依给药途径划分

  • 静脉注射
  • 口服
  • 皮下注射

第十一章 催产素受体抑制剂市场（以最终用户划分）

  • 医院
  • 研究所
  • 专科诊所

12. 催产素受体抑制剂市场依分销管道划分

  • 离线
  • 在线的

13. 各地区催产素受体抑制剂市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 催产素受体抑制剂市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国催产素受体抑制剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国催产素受体抑制剂市场

第十七章 中国催产素受体抑制剂市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alembic Pharmaceuticals Limited
  • Bionika Pharmaceuticals
  • Chengdu Shengnuo Biopharm Co., Ltd.
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Ferring Pharmaceuticals A/S
  • Fresenius Kabi AG
  • Gland Pharma Limited
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Limited
  • Novartis AG
  • ObsEva SA
  • Pfizer Inc.
  • Shanxi Weiqida Guangming Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Yangtze River Pharmaceutical Group Co., Ltd.
  • Zuventus Healthcare Limited
Product Code: MRR-7A380DA7C453

The Oxytocin Receptor Inhibitors Market was valued at USD 1.32 billion in 2025 and is projected to grow to USD 1.45 billion in 2026, with a CAGR of 10.58%, reaching USD 2.68 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.32 billion
Estimated Year [2026] USD 1.45 billion
Forecast Year [2032] USD 2.68 billion
CAGR (%) 10.58%

Contextual introduction to the evolving scientific, clinical, and operational realities shaping development of oxytocin receptor inhibitors across therapeutic areas

The oxytocin receptor inhibitors landscape occupies an interdisciplinary intersection of neuropharmacology, maternal health, and psychiatric therapeutics, and it has attracted growing attention from clinical researchers, biotechnology firms, and specialty clinics. Advances in receptor biology and a deeper understanding of oxytocin's role in social behavior, uterine contractility, and neuroendocrine signaling have reframed development priorities, broadening the scope of potential indications beyond historical use cases. As a result, a diversified pipeline now spans both peptide and small molecule modalities, and developers are increasingly pursuing differentiated delivery strategies and patient-centric formulations.

Despite this momentum, the field faces scientific and operational challenges that demand strategic clarity. Key obstacles include the inherent complexity of central nervous system targeting for neuropsychiatric indications, the stability and manufacturability constraints associated with peptide-based candidates, and the need for robust biomarkers to demonstrate target engagement and clinical benefit. In response, sponsors are integrating translational endpoints, adaptive trial designs, and real-world evidence to de-risk programs. This introduction synthesizes those dynamics to set the stage for the subsequent analysis, highlighting the interplay between therapeutic promise and the pragmatic considerations that determine which programs progress to late-stage development and clinical adoption.

How advances in precision biology, formulation engineering, and clinical trial digitization are fundamentally changing development pathways for oxytocin receptor inhibitors

The last several years have seen several transformative shifts that are reshaping how oxytocin receptor inhibitors are discovered, developed, and delivered to patients. First, the application of precision biology and biomarker-enabled trials has moved target validation beyond phenomenology to quantitative measures of receptor occupancy and downstream signaling, allowing sponsors to prioritize candidates with stronger translational rationale. Second, innovations in medicinal chemistry and formulation science have narrowed the performance gap between peptide and small molecule approaches, expanding the feasibility of oral and self-administered options that improve patient adherence.

Concurrently, consolidation in contract manufacturing and increased investment in peptide synthesis infrastructure have lowered technical barriers, albeit unevenly across regions. Digital tools for patient recruitment, remote monitoring, and decentralized trial operations have accelerated enrollment for neuropsychiatric and maternal health studies, while regulatory agencies are signaling more constructive paths for adaptive and digitized evidence packages. Finally, cross-sector partnerships between academic centers, specialty clinics, and industry have become a dominant model for de-risking early clinical proof-of-concept work, enabling resource-sharing and more rapid iteration of clinical protocols. Taken together, these shifts have compressed development timelines in some program types while elevating expectations for demonstrable mechanistic and clinical benefit.

Assessing how tariff measures that affect pharmaceutical inputs and finished products cumulatively reshape supply chains, procurement strategies, and clinical supply continuity for developers

The imposition or escalation of tariffs affecting pharmaceutical raw materials, peptide synthesis inputs, and finished biologic or small molecule imports can produce a cumulative set of effects that ripple across supply chains, manufacturing economics, and clinical development logistics. Where tariff measures increase the cost of essential reagents or contract-manufactured intermediates, sponsors are likely to reassess sourcing strategies, accelerate qualification of secondary suppliers, and in some cases pursue nearshoring of critical steps to reduce exposure to cross-border trade volatility. These adaptations can mitigate risk but typically require upfront investment in supplier audits, regulatory dossiers, and scale-up activity.

Tariff-driven cost inflation also influences prioritization decisions within portfolios. Developers managing constrained budgets may shift resources toward programs with lower raw material intensity, shorter development cycles, or stronger prospects for non-dilutive funding through public-private partnerships. Clinical trial operations can be affected when investigational product supplies cross borders for multinational studies; increased duties or customs complexity may necessitate larger buffer inventories, more conservative shipping schedules, and expanded documentation to ensure continuity of supply. In parallel, payer and provider conversations around pricing and reimbursement may be affected by changes in production economics, prompting earlier engagement with health systems to align product design with delivery models that contain downstream costs. In short, tariffs act as a structural stress test that amplifies the importance of procurement resilience, diversified supplier networks, and regulatory foresight.

Interpreting a multidimensional segmentation framework that links indication priorities, molecule classes, administration routes, care settings, and distribution channels to strategic development choices

A rigorous segmentation framework provides practical insight into clinical priorities, formulation choices, and commercialization pathways for oxytocin receptor inhibitors. Based on indication, the field encompasses Autism Spectrum Disorder, Postpartum Hemorrhage, Preterm Labor, and Schizophrenia, each of which carries distinct unmet needs, clinical endpoints, and regulatory considerations that influence trial design and route of administration. Therapeutic focus on Autism Spectrum Disorder and Schizophrenia emphasizes central nervous system penetration and long-term safety, while postpartum hemorrhage and preterm labor prioritize rapid onset, predictable uterotonic modulation, and integration with obstetric care pathways.

Based on molecule type, the landscape divides between Peptide and Small Molecule approaches, with peptides offering high receptor specificity but presenting stability and formulation challenges, and small molecules promising oral bioavailability and simplified supply chains at the potential expense of selectivity. Based on route of administration, developers explore Intravenous, Oral, and Subcutaneous options, with Intravenous delivery further subdivided into Bolus Injection and Continuous Infusion to meet acute versus sustained therapeutic needs, and Subcutaneous approaches further differentiated into Clinician-Administered and Self-Administered formats to support inpatient and outpatient care models. Based on end user, the most relevant settings include Hospitals, Research Institutes, and Specialty Clinics, each exerting different demands on training, cold-chain logistics, and real-world evidence generation. Finally, based on distribution channel, supply pathways encompass Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, where the Hospital Pharmacy segment is further distinguished between Private and Public institutions, and the Online Pharmacy category is further split between Direct To Consumer and Third Party Marketplace routes, shaping reimbursement interactions and patient access strategies.

Understanding how these segmentation dimensions interact is essential for prioritizing clinical endpoints, designing patient-centric delivery formats, and structuring distribution agreements that reflect payer behavior and care setting requirements. Combining indication-driven endpoint selection with molecule type and route-of-administration constraints clarifies which programs are likely to align with hospitals versus retail or online distribution, and which development investments will yield the greatest operational leverage.

Comparing the distinct regulatory, clinical research, manufacturing, and access dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific regions

Regional dynamics exert a decisive influence on research infrastructure, regulatory timelines, manufacturing capabilities, and commercial access for oxytocin receptor inhibitors. In the Americas, the research ecosystem benefits from large academic networks, established clinical trial sites with experience in neuropsychiatric and obstetric studies, and a sophisticated payer environment that prioritizes evidence of comparative effectiveness and health-economic value. This combination supports high-intensity clinical programs and creates opportunities for early collaborations with hospital systems to validate delivery models and real-world outcomes.

Europe, Middle East & Africa features a heterogeneous regulatory and reimbursement landscape where regional harmonization efforts coexist with country-level variations that affect trial approvals, pricing negotiations, and distribution agreements. Many countries within this geography excel in translational neuroscience research and maintain strong public-private partnerships, but sponsors must navigate diverse procurement rules and clinician practice patterns. Asia-Pacific presents a fast-growing research and manufacturing base with expanding contract development and manufacturing organization capabilities, increasing talent pools for peptide synthesis, and highly competitive cost structures. Regulatory modernization in several Asia-Pacific jurisdictions has accelerated access to clinical trial pathways, yet clinical adoption and reimbursement often depend on local-generation of outcomes data and tailored pricing strategies. Each region therefore demands bespoke engagement plans that align clinical development with regulatory expectations, manufacturing footprints, and payer evidence requirements.

Strategic behaviors and partnership models among innovators, larger pharmaceutical sponsors, and manufacturing partners that determine who advances oxytocin receptor inhibitor programs

Companies active in the oxytocin receptor inhibitor domain are adopting a range of strategic postures that reflect their resource base, technological capabilities, and pipeline maturity. Biotech innovators are frequently focused on early-stage differentiation through novel chemistry, delivery platforms, and biomarker strategies designed to demonstrate mechanism-based signals in small, quickly executed proof-of-concept studies. These sponsors tend to favor flexible collaboration models with academic centers and contract research organizations to accelerate translational work while conserving capital.

Larger pharmaceutical companies and specialty therapeutics firms are more likely to invest in later-stage clinical validation, scaled manufacturing partnerships, and integrated commercialization planning, seeking to augment internal capabilities with licensing or acquisition of promising peptide or small molecule candidates. Contract development and manufacturing organizations are intensifying investments in peptide synthesis capacity, aseptic filling, and cold-chain logistics to capture demand from both emerging and established players. Across the ecosystem, successful corporate strategies emphasize agile partnering, intellectual property clarity, and early payer engagement to translate clinical signals into credible value propositions for providers and health systems. Observing these behaviors can guide prospective collaborators in positioning assets, structuring deals, and anticipating competitive moves.

Actionable strategic priorities for sponsors to align biomarker-driven development, supply chain resilience, payer engagement, and commercialization for sustainable success

Industry leaders seeking to translate scientific potential into durable therapeutic options for patients should pursue an integrated set of actions that balance scientific rigor with operational resilience. First, prioritize translational biomarker programs that can provide early, objective signals of target engagement and pharmacodynamic effect, thereby improving go/no-go decision quality and facilitating regulatory dialogues. Simultaneously, allocate resources to chemistry and formulation strategies that maximize stability and enable patient-preferred routes of administration, which in turn expand adoption pathways beyond hospital settings.

Second, fortify supply chains by qualifying multiple suppliers for critical reagents, exploring regional manufacturing partnerships to mitigate trade exposure, and investing in inventory management that supports multinational trials. Third, engage payers and health systems early to align clinical endpoints with value-based measures and to develop pragmatic evidence-generation plans that include real-world outcomes. Fourth, establish flexible collaboration frameworks with academic centers and contract research organizations to accelerate proof-of-concept work while preserving optionality for partnering or acquisition. Finally, build commercialization playbooks that reflect distribution realities-differentiating approaches for hospital-centric delivery versus self-administered or online pharmacy channels-and invest in clinician education and patient support programs to drive uptake in specialty care pathways.

Methodological approach combining primary expert interviews, systematic literature and registry review, patent mapping, and manufacturing and distribution assessments to ensure evidence robustness

The research methodology underpinning this analysis integrates multiple complementary approaches to ensure robust, reproducible insights. Primary qualitative work comprised in-depth interviews with clinicians, clinical trial investigators, regulatory affairs specialists, and supply chain managers who have direct experience with neuropsychiatric and obstetric investigational programs. These interviews were combined with a systematic review of peer-reviewed literature, clinical trial registries, and regulatory guidance documents to validate mechanism-of-action hypotheses, clarify endpoint selection, and identify prevailing trial design innovations.

Supplementing qualitative insights, the study mapped patent landscapes and public filings to track molecule-type differentiation and freedom-to-operate considerations, and it assessed manufacturing capabilities through engagements with contract development and manufacturing partners. The research also included structured assessments of distribution and care delivery models by reviewing hospital formularies, pharmacy channel dynamics, and clinician workflows. Limitations of the methodology include the evolving nature of early clinical data and the variable transparency of proprietary development programs; where gaps existed, triangulation across multiple expert sources was used to reduce bias and enhance confidence in conclusions.

Synthesis of scientific promise, operational constraints, and strategic pathways to convert oxytocin receptor inhibitor research into clinically adopted therapies

The development environment for oxytocin receptor inhibitors is characterized by strong scientific rationale, growing translational sophistication, and a complex set of operational trade-offs. Advances in biomarker science, formulation engineering, and trial decentralization create opportunities to bring differentiated therapies to patients across neuropsychiatric and obstetric indications. At the same time, program sponsors must navigate practical constraints related to peptide manufacturability, supply chain exposure, regulatory variation across regions, and the need to demonstrate meaningful clinical benefit that aligns with payer expectations.

A coherent strategy that integrates early mechanistic validation, diversified manufacturing and sourcing, proactive payer engagement, and tailored commercialization planning will be essential to convert promising science into adopted therapies. By aligning technical development choices with care settings and distribution pathways, sponsors can increase the probability that successful clinical outcomes translate into real-world access and sustained clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oxytocin Receptor Inhibitors Market, by Indication

  • 8.1. Autism Spectrum Disorder
  • 8.2. Postpartum Hemorrhage
  • 8.3. Preterm Labor
  • 8.4. Schizophrenia

9. Oxytocin Receptor Inhibitors Market, by Molecule Type

  • 9.1. Peptide
  • 9.2. Small Molecule

10. Oxytocin Receptor Inhibitors Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Oxytocin Receptor Inhibitors Market, by End User

  • 11.1. Hospitals
  • 11.2. Research Institutes
  • 11.3. Specialty Clinics

12. Oxytocin Receptor Inhibitors Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Oxytocin Receptor Inhibitors Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Oxytocin Receptor Inhibitors Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oxytocin Receptor Inhibitors Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Oxytocin Receptor Inhibitors Market

17. China Oxytocin Receptor Inhibitors Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alembic Pharmaceuticals Limited
  • 18.6. Bionika Pharmaceuticals
  • 18.7. Chengdu Shengnuo Biopharm Co., Ltd.
  • 18.8. Cipla Limited
  • 18.9. Dr. Reddy's Laboratories Limited
  • 18.10. Ferring Pharmaceuticals A/S
  • 18.11. Fresenius Kabi AG
  • 18.12. Gland Pharma Limited
  • 18.13. GlaxoSmithKline plc
  • 18.14. Hikma Pharmaceuticals PLC
  • 18.15. Intas Pharmaceuticals Limited
  • 18.16. Novartis AG
  • 18.17. ObsEva SA
  • 18.18. Pfizer Inc.
  • 18.19. Shanxi Weiqida Guangming Pharmaceutical Co., Ltd.
  • 18.20. Sun Pharmaceutical Industries Limited
  • 18.21. Teva Pharmaceutical Industries Ltd.
  • 18.22. Viatris Inc.
  • 18.23. Yangtze River Pharmaceutical Group Co., Ltd.
  • 18.24. Zuventus Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY AUTISM SPECTRUM DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY AUTISM SPECTRUM DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY AUTISM SPECTRUM DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY POSTPARTUM HEMORRHAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY POSTPARTUM HEMORRHAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY POSTPARTUM HEMORRHAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY PRETERM LABOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY PRETERM LABOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY PRETERM LABOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY SCHIZOPHRENIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY SCHIZOPHRENIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. GCC OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. GCC OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. GCC OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. GCC OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GCC OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. G7 OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. G7 OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. G7 OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. G7 OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. G7 OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. NATO OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. NATO OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. NATO OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. NATO OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. NATO OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA OXYTOCIN RECEPTOR INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)